Cue Biopharma Q1 net loss narrows on lower R&D costs

Cue Biopharma

14/05/2026 21:25

Overview

US immunotherapy developer's Q1 revenue rose sharply yr/yr, driven by collaboration milestone payments

Net loss for Q1 narrowed, mainly due to lower R&D expenses and employee attrition

Company completed $30 mln private placement and received $7.5 mln milestone payment

Outlook

Cue expects to submit IND amendment for CUE-221 to FDA in H2 2026

Company expects results from China Phase 2 study of CUE-221 in H2 2026

Cue expects to submit IND for CUE-401 and start Phase 1 trial by year-end 2026

Result Drivers

COLLABORATION REVENUE - Q1 revenue increase was mainly due to milestone payment from Boehringer Ingelheim collaboration

LOWER R&D EXPENSES - Decrease in research and development costs was primarily due to lower clinical trial costs for CUE-100 series and reduced employee compensation from attrition

Company press release: ID:nGNX9fDyyM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$5.69 mln
Q1 Net Income
-$5.18 mln
Q1 Basic EPS
-$1.08
Q1 Income From Operations
-$5.35 mln
Q1 Operating Expenses
$11.04 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cue Biopharma Inc is $115.00, about 290.2% above its May 13 closing price of $29.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)